Ordinary Shares, nominal value EUR0.05 per share

Innate Pharma SA

117 Avenue de Luminy, Marseille, I0, 13009

Item 2(a) is hereby amended and supplemented as follows: This Statement is being filed by the following beneficial owners of Ordinary Shares: 1. Bpifrance Participations S.A., a societe anonyme incorporated under the laws of the Republic of France 2. EPIC Bpifrance, a French public institution of industrial and commercial nature 3. Bpifrance S.A., a societe anonyme incorporated under the laws of the Republic of France 4. Caisse des depots et consignations, a French special public entity (etablissement special) 5. CDC Croissance S.A., a societe anonyme incorporated under the laws of the Republic of France

Item 2(b) is hereby amended and supplemented as follows: The principal address for CDC Croissance is 209, rue de l'Universite 75007 Paris. CDC Croissance, a 100% subsidiary of CDC, is a management company which manages a range of equity funds for the CDC Group clients. Specializing in small and mid-cap listed companies, the management company is accredited by the French Autorite des marches financiers.

Information concerning the executive officers and directors of Bpifrance Participations, CDC Croissance, CDC, EPIC and Bpifrance required to be disclosed in response to Item 2 and General Instruction C to Schedule 13D is provided in Exhibit 99.2 to this Amendment and incorporated herein by reference.

None of the Reporting Persons, nor, to the best of their knowledge, any of the persons referred to in Exhibit 99.2 has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: As of the date hereof, (i) Bpifrance Participations holds directly 6,389,406 Ordinary Shares, which represents approximately 6.9% of the Issuer's outstanding Ordinary Shares, and approximately 6.9% of outstanding theoretical voting rights, and (ii) CDC Croissance holds 930,023 Ordinary Shares, which represents approximately 1.0% of the Issuer's outstanding Ordinary Shares, and approximately 1.0% of outstanding theoretical voting rights. As of the date hereof, none of Bpifrance, EPIC or CDC holds any Ordinary Shares directly. Bpifrance may be deemed to be the beneficial owner of 6,389,406 Ordinary Shares, indirectly through its 99.99% ownership of Bpifrance Participations. EPIC may be deemed to be the beneficial owners of 6,389,406 Ordinary Shares, indirectly through its joint ownership and control of Bpifrance. CDC may be deemed to be the beneficial owner of (x) 6,389,406 Ordinary Shares, indirectly through its joint ownership and control of Bpifrance and (y) 930,023 Ordinary Shares, indirectly through its ownership of CDC Croissance. This Amendment is being filed to reflect a decrease in the Reporting Persons' percentage ownership of the Issuer's Ordinary Shares, which resulted solely from an increase in the number of Ordinary Shares outstanding since the filing of Amendment No. 2 to Schedule 13D and is not due to any transactions in the Ordinary Shares by the Reporting Persons. The percentage of Ordinary Shares and voting rights beneficially owned by each Reporting Person is based on 92,157,148 outstanding Ordinary Shares and 92,944,368 outstanding voting rights of the Issuer, as of April 25, 2025, as published by the Issuer on April 28, 2025. The amount of outstanding Ordinary Shares and voting rights disclosed in the prior sentence is calculated under U.S. law, which requires treasury shares to be excluded from the calculation of outstanding shares. Under French law, treasury shares are required to be included in the calculation of outstanding shares. Using the French law requirements, the Issuer has 92,175,723 outstanding Ordinary Shares and 92,962,943 outstanding theoretical voting rights, and (i) Bpifrance Participations' Ordinary Share holdings represent approximately 6.9% of the Issuer's outstanding Ordinary Shares, and its voting rights represent approximately 6.9% of outstanding theoretical voting rights, and (ii) CDC Croissance's Ordinary Share holdings represent approximately 1.0% of the Issuer's outstanding Ordinary Shares, and its voting rights represent approximately 1.0% of outstanding theoretical voting rights.

Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: See the information contained on the cover pages of this Amendment, which is incorporated herein by reference.

Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: There have been no reportable transactions with respect to the Ordinary Shares of the Issuer within the last 60 days by the Reporting Persons, or, to the best of their knowledge, any of the persons referred to in Exhibit 99.2.